Impact of comorbidities on the prognosis of pediatric vasovagal syncope  

作　　者：Ya-Ru Wang Xue-Ying Li Jun-Bao Du Yan Sun Wen-Rui Xu Yu-Li Wang Ying Liao Hong-Fang Jin 

机构地区：[1]Department of Pediatrics,Peking University First Hospital,No.1 Xi’an-men Street,West District,Beijing,100034,China [2]Department of Medical Statistics,Peking University First Hospital,Beijing,China [3]Key Laboratory of Molecular Cardiovascular Sciences,Ministry of Education,Beijing,China

出　　处：《World Journal of Pediatrics》2022年第9期624-628,共5页世界儿科杂志（英文版）

基　　金：supported by the Peking University Clinical Scientist Program(BMU2019LCKXJ001);the Fundamental Research Funds for the Central Universities,China.Clinical Medicine Plus X-Young Scholars Project(PKU2022LCXQ028);the Fundamental Research Funds for the Central Universities,China.Multi-center Study Project,Peking University First Hospital,China.

摘　　要：Vasovagal syncope(VVS)is the primary entity of neurally mediated syncope(NMS)in childhood,and its prognosis is usually considered benign.However,it is found in clini-cal practice that some children with VVS appear to have a frequent recurrence of syncope and poor response to treat-ment[1],which might seriously affect their quality of life[2].In recent years,an increasing number of comorbidities of VVS have been reported.Liao et al.found that 31%of pediatric patients with NMS suffered from allergic disease[3],and Vallejo M reported that more than 50%of patients had headaches[4].These comorbidities might make the clinical manifestations even more complex.However,until now,it has been unclear whether comorbidities are associated with the prognosis of children and adolescents suffering from VVS.Therefore,the present study was conducted to examine whether there is any impact of comorbidities on the prognosis of pediatric VVS to better understand the outcome and management of children and adolescents with VVS.

关 键 词：SYNCOPE MORBID PEDIATRIC 

分 类 号：R725.4[医药卫生—儿科]